OliX Pharmaceuticals,Inc (226950.KQ)
KRW 18430.0
(-6.07%)
KRW 18430.0
(-6.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -11.13 Billion KRW | 23.82% |
| 2022 | -24.2 Billion KRW | 9.77% |
| 2021 | -25.95 Billion KRW | -50.26% |
| 2020 | -19.07 Billion KRW | -4.94% |
| 2019 | -13.46 Billion KRW | -83.54% |
| 2018 | -7.19 Billion KRW | -55.02% |
| 2017 | -4.75 Billion KRW | -36.78% |
| 2016 | -3.51 Billion KRW | -73.66% |
| 2015 | -1.89 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.44 Billion KRW | -264.4% |
| 2024 Q2 | -3.12 Billion KRW | -5.05% |
| 2023 Q1 | -7.17 Billion KRW | -191.39% |
| 2023 FY | - KRW | 23.82% |
| 2023 Q3 | -4.37 Billion KRW | 36.82% |
| 2023 Q2 | -6.92 Billion KRW | 3.49% |
| 2023 Q4 | 2.93 Billion KRW | 167.1% |
| 2022 Q3 | -4.19 Billion KRW | 41.92% |
| 2022 Q1 | -7.21 Billion KRW | -15.11% |
| 2022 FY | - KRW | 9.77% |
| 2022 Q4 | -2.46 Billion KRW | 41.33% |
| 2022 Q2 | -7.22 Billion KRW | -0.15% |
| 2021 Q1 | -5 Billion KRW | -31.07% |
| 2021 FY | - KRW | -50.26% |
| 2021 Q4 | -6.26 Billion KRW | 16.98% |
| 2021 Q2 | -5.73 Billion KRW | -14.64% |
| 2021 Q3 | -7.55 Billion KRW | -31.58% |
| 2020 Q3 | -4 Billion KRW | 9.81% |
| 2020 Q2 | -4.44 Billion KRW | -56.58% |
| 2020 Q1 | -2.83 Billion KRW | 43.01% |
| 2020 Q4 | -3.81 Billion KRW | 4.63% |
| 2020 FY | - KRW | -4.94% |
| 2019 Q2 | -3.48 Billion KRW | -42.59% |
| 2019 Q1 | -2.44 Billion KRW | -30.97% |
| 2019 Q3 | -3.43 Billion KRW | 1.25% |
| 2019 Q4 | -4.97 Billion KRW | -44.66% |
| 2019 FY | - KRW | -83.54% |
| 2018 Q4 | -1.86 Billion KRW | 1.8% |
| 2018 FY | - KRW | -55.02% |
| 2018 Q3 | -1.89 Billion KRW | 7.81% |
| 2018 Q2 | -2.06 Billion KRW | -8.36% |
| 2018 Q1 | -1.9 Billion KRW | 0.0% |
| 2017 FY | - KRW | -36.78% |
| 2016 FY | - KRW | -73.66% |
| 2015 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 93.537% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | -78.6% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 202.419% |
| Bioneer Corporation | 10.04 Billion KRW | 210.872% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | -2443.271% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 42.578% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 73.982% |
| Helixmith Co., Ltd | -53 Billion KRW | 78.992% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 115.887% |
| Medy-Tox Inc. | 32.69 Billion KRW | 134.054% |
| Peptron, Inc. | -12.65 Billion KRW | 11.979% |
| Amicogen, Inc. | 13.95 Billion KRW | 179.803% |
| Genexine, Inc. | -40.87 Billion KRW | 72.76% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | 235.305% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 84.401% |
| ALTEOGEN Inc. | 440.04 Million KRW | 2630.456% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 110.681% |
| SillaJen, Inc. | -17.35 Billion KRW | 35.83% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 201.156% |
| Genomictree Inc. | -6.33 Billion KRW | -75.858% |
| MedPacto, Inc. | -32.6 Billion KRW | 65.852% |
| D&D Pharmatech | -9.05 Billion KRW | -22.932% |
| EASY BIO,Inc. | 24.32 Billion KRW | 145.78% |
| GI Innovation, Inc. | -51.33 Billion KRW | 78.307% |